Document Detail


Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions.
MedLine Citation:
PMID:  18288747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In selected patient cohorts the polymer-free rapamycin-eluting YUKON stent (A) has demonstrated noninferiority compared with the polymer-based paclitaxel-eluting TAXUS stent (B). To test for equivalency in unselected real-world patients with coronary lesions of various complexities, we retrospectively compared both stent designs. METHODS: A total of 410 patients with symptomatic CAD were successfully treated with A (n = 205) or with B (n = 205). Baseline clinical characteristics, coronary lesion location, lesion length, and the number of stents implanted per lesion were equally distributed between the treatment groups. All patients underwent QCA-analysis at baseline. Clinical follow-up with assessment of MACE and noncardiac deaths was obtained at 30 days and 6 months. RESULTS: Nominal stent diameter was 2.96 +/- 0.38 mm in Group A vs. 3.05 +/- 0.42 mm in Group B (P = 0.2); nominal length of stented segmentwas 22.97 +/-13.0 mm vs. 23.63 +/- 10.0 (P = 0.56). Analysis of MACE after 6 months resulted in one angiographically documented stent thrombosis causing MI in B (0.2%) vs. none in A. No other MI or cardiac deaths occurred in either group, while two noncardiac deaths in A (1.0%) were reported. Fifteen target lesion revascularizations (7.3%) were performed in A vs. 7 (3.4%) in B. Differences in study endpoints at 6 months did not reach statistical significance (P > 0.05). CONCLUSIONS: Up to 6 months after PCI of real-world coronary lesions, there were no statistically significant differences in MACE between patients treated with the polymer-free rapamycin-eluting YUKON stent and the polymer-based paclitaxel-eluting TAXUS stent.
Authors:
Johannes Ruef; Hans Störger; Franz Schwarz; Jürgen Haase
Related Documents :
18046527 - Troponin level and efficacy of abciximab in patients with acute coronary syndromes unde...
15117037 - Stent placement compared with balloon angioplasty for obstructed coronary artery diseas...
22007257 - Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum li...
19952467 - Comparison of triple antiplatelet therapy including triflusal and conventional dual the...
11211537 - Coronary artery bypass graft outcome: the trinidad and tobago experience.
23225077 - Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nep...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  71     ISSN:  1522-726X     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-26     Completed Date:  2008-03-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  333-9     Citation Subset:  IM    
Copyright Information:
(c) 2008 Wiley-Liss, Inc.
Affiliation:
Red Cross Hospital Cardiology Center, Frankfurt, Germany. j.ruef@kardiocentrum-ffm.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Analysis of Variance
Angioplasty, Transluminal, Percutaneous Coronary / methods
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Aspirin / therapeutic use
Cohort Studies
Coronary Angiography / methods
Coronary Restenosis / epidemiology,  radiography*
Coronary Stenosis / mortality,  radiography*,  therapy*
Drug-Eluting Stents*
Female
Humans
Male
Middle Aged
Paclitaxel / therapeutic use*
Polymers
Probability
Prognosis
Reference Values
Risk Assessment
Severity of Illness Index
Sirolimus / therapeutic use*
Survival Analysis
Treatment Outcome
Vascular Patency / physiology
Vasodilator Agents / therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Polymers; 0/Vasodilator Agents; 33069-62-4/Paclitaxel; 50-78-2/Aspirin; 53123-88-9/Sirolimus
Comments/Corrections
Comment In:
Catheter Cardiovasc Interv. 2008 Feb 15;71(3):340-1   [PMID:  18288754 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 pati...
Next Document:  Cardiac perforation and tamponade 3 months after transcatheter PFO closure by STARFlex device: A cas...